NEW YORK (GenomeWeb News) – The Institute of Cancer Research, London has granted Oxford Gene Technology a license to develop a panel of diagnostic and prognostic prostate cancer microRNA biomarkers into a new assay, OGT said today.

The license is the result of a three-year collaboration, under which ICR and OGT discovered new microRNA biomarkers with a range of applications for the diagnosis, prognosis, treatment planning, and monitoring of prostate cancer.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: spatiotemporal study of lncRNA expression, role of extrachromosomal, circular DNAs in yeast, and more.

A European team has launched a four-year study to develop a test to gauge cervical, ovarian, uterine, or aggressive breast cancer risk in women.

As interest in personalized medicine grows, government contractors are entering the field, the Washington Post reports.

In PLOS this week: Plasmodium knowlesi population genetics, oral microbiome of infants and children, and more.